University of Montréal
Blood cancer type
Self-Assembling Multi-Subunit Chimeric Antigen Receptors to Target Leukemia
Current therapies using chimeric antigen receptor (CAR) therapy show great success in treating patients with various types of leukemia. However, this approach has been fraught with pitfalls such as aberrations in receptor signaling, which can cause severe side effects such as death. One current pitfall is that current CARs have the ability to compete or associate with endogenous receptors. The novel CAR architectures proposed in this research will abrogate these interactions and enable a more predictive immune response outcome.